Get the Stockscreener App
1.70
0.58%
-0.01
Milestone Pharmaceuticals Inc stock is traded at $1.70, with a volume of 761.13K.
It is down -0.58% in the last 24 hours and up +10.39% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.71
Open:
$1.7
24h Volume:
761.13K
Relative Volume:
0.56
Market Cap:
$144.49M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.223
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+0.00%
1M Performance:
+10.39%
6M Performance:
-16.67%
1Y Performance:
+18.06%
1-Day Range:
$1.68
$1.72
1-Week Range:
$1.62
$1.75
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.70 | 144.44M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals shares rise 1.80% after-hours following positive corporate updates from NRx Pharmaceuticals. - AInvest
Milestone Pharmaceuticals: Strategic Momentum and Growth Catalysts in 2025 - AInvest
Milestone® Pharmaceuticals to Present at Upcoming Conferences - The Globe and Mail
Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c) - MSN
Milestone Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftJuly 2025 Breakouts & Growth Focused Entry Point Reports - beatles.ru
Milestone Scientific to Report Q2 2025 Financial Results and Business Update - AInvest
Milestone Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus - TipRanks
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Announces FDA Acceptance of CARDAMYST™ CRL Response and Secures $170 Million in Public Offering - Quiver Quantitative
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Short Interest Drops in Milestone Pharmaceuticals Inc. After RallyCapital Protection Trading Strategies Gain Interest - metal.it
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
What drives Milestone Pharmaceuticals Inc. stock priceAchieve rapid portfolio growth with smart picks - Jammu Links News
What analysts say about Milestone Pharmaceuticals Inc. stockCapitalize on market momentum for maximum profit - Jammu Links News
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Consistently outstanding ROI - Jammu Links News
How many analysts rate Milestone Pharmaceuticals Inc. as a “Buy”Exponential return rates - Jammu Links News
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedFree Daily Trading Room Entry - Jammu Links News
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Milestone Pharmaceuticals Inc.Capitalize on emerging trends for profits - Jammu Links News
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What catalysts could drive Milestone Pharmaceuticals Inc. stock higher in 2025Invest confidently with advanced analysis tools - Jammu Links News
How does Milestone Pharmaceuticals Inc. compare to its industry peersMaximize your gains with professional insights - Jammu Links News
Stock Market News for Aug 1, 2025 - The Globe and Mail
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Trading Bots Trigger Alerts on Milestone Pharmaceuticals Inc. ActivityReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Can Milestone Pharmaceuticals Inc. hit a new high this monthSwing Setup With Technical Confirmation Explained - metal.it
RSI Suggests Rebound May Be Near in Milestone Pharmaceuticals Inc.Accurate Buy Point for Momentum Stocks Detected - metal.it
Published on: 2025-07-29 04:32:28 - beatles.ru
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - Jammu Links News
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - Jammu Links News
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):